RxDoctor Payments Data

Michele Maouad, MD

Dermatology · Morgantown, WVNPI 1013991355

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.1% of the total across 342 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,321 and has fallen 51.7% since, to $638 in 2025.

$6,152in general payments, 2019–2025

Across 342 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$936
  • Johnson & Johnson$765
  • Lilly USA, LLC$586
  • Journey Medical Corporation$559
  • Galderma Laboratories, L.p.$497
  • E.r. Squibb & Sons, L.L.C.$421
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,66792%
  • Education$4858%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,152 in reported general payments places this provider in the 70th percentile of 39 dermatology providers in West Virginia.

See all dermatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$170,602
Medicare patients
608
Services billed
2,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast32$192,861
Humira(Cf) PenAdalimumab23$158,012
Dupixent PenDupilumab28$108,615
Cosentyx Unoready PenSecukinumab11$82,147
Tacrolimus23$4,873
Clobetasol Propionate58$3,260
Metronidazole35$2,356
Doxycycline Hyclate54$1,836
Tretinoin12$1,283
CiclopiroxCiclopirox Olamine40$886
ValacyclovirValacyclovir Hcl13$526
Ketoconazole39$522
Triamcinolone Acetonide52$362
Halobetasol Propionate17$316
Fluconazole17$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$419$192,86132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 39 dermatology providers in West Virginia.

Other dermatology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →